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Description
Field of the invention
[0001] This disclosure relates to a composition com-
prising chitosan for use in prevention and/or treatment
of incontinence and/or impotence in a subject undergoing
prostatectomy.
Background of the invention
[0002] Prostate cancer is the most common cancer
among European and American men. Treatment of pros-
tate cancer commonly involves surgical therapy including
radical prostatectomy. However, despite the increasing
use of nerve-sparing techniques, such as robot-assisted
surgery, urinary incontinence and erectile dysfunction re-
main major adverse consequences of radical prostatec-
tomy.
[0003] Cavernous nerve injury caused by different fac-
tors, including mechanical traction damage to the neu-
rovascular bundle during mobilization of the prostate, as
well as post-operative inflammation of the neurovascular
bundle, is the main reason for post-surgical erectile dys-
function.
[0004] Different materials have been tested to reduce
the rate of erectile dysfunction, in order to ultimately im-
prove the quality of life for patients.
[0005] For example, sural nerve grafts have been used
as interponates to replace completely resected neurov-
ascular bundles in patients, leading, however, to rather
unpredictable and unsatisfactory results (Scardino and
Kim, "Rationale for and results of nerve grafting during
radical prostatectomy", Urology 2001, 57, 1016).
[0006] In animal experiments, a 2 mm rat cavernous
nerve gap was either bridged with a biodegradable pol-
yester conduit optionally containing collagen sponge
(Hisasue et al., Cavernous nerve reconstruction with a
biodegradable conduit graft and collagen sponge in the
rat", J Urol 2005, 173, 286), or with a cross-linked alginate
gel sheet (Matsuura et al., Cavernous nerve regeneration
by biodegradable alginate gel sponge sheet placement
without sutures", Urology 2006; 68, 1366).
[0007] However, as the human neurovascular bundle
is composed of a heterogeneous network of nerve fibers
and blood vessels, unlike the cable-like structure in the
rat, results cannot be transferred from the rat model to
the clinical situation.
[0008] Modern surgery focuses on nerve-sparing tech-
niques which results in an increased restoration of erec-
tile function by preserving the integrity of the neurovas-
cular bundles.
[0009] While mechanical damage to the neurovascular
bundle can be minimized by the experienced surgeon,
the post-surgical inflammation remains a problem, which
has to be addressed.
[0010] For example, a biodegradable polyester mem-
brane containing brain-derived neurotrophic factor and
adipose-derived stem cells has been tested in a rat cav-
ernous nerve crush injury model, and an improved erec-
tile function was observed compared to the non-cell con-
taining group (Piao et al., "Therapeutic effect of adipose-
derived stem cells and BDNF-immobilized PLGA mem-
brane in a rat model of cavernous nerve injury", J Sex
Med 2012, 9, 1968).
[0011] The application of growth factors and anti-in-
flammatory substances to preserve and regenerate the
prostatic neurovascular bundle has been further ad-
vanced by the use of dehydrated human amnion/chorion
membranes as source of neurotrophic factors and cy-
tokines.
[0012] In the clinical setting, at one month post-sur-
gery, approximately 30% of the patients regained poten-
cy and urinary continence in both the treated and control
groups while at three months, approximately 70% of the
patients in the treated group were potent and 95% con-
tinent, with slightly lower numbers observed for the con-
trol group (Patel et al., "Dehydrated human amnion/cho-
rion membrane allograft nerve wrap around the prostatic
neurovascular bundle accelerates early return to conti-
nence and potency following robot-assisted radical pros-
tatectomy: propensity score-matched analysis", Eur Urol
2015, 67, 977).
[0013] As both the manufacture process and the reg-
ulatory approval and commercialization of a medical de-
vice in combination with growth factors and cellular com-
ponents are demanding and expensive processes, there
is still a need for simple technical solutions, preferably
based on biocompatible and biodegradable components,
that can efficiently support the early return of continence
and potency in patients following prostatectomy.
Summary of the invention
[0014] The object of the present disclosure is to provide
a biocompatible and biodegradable composition, which
overcomes the above reported drawbacks.
[0015] The above object is achieved thanks to the sub-
ject matter recalled specifically in the ensuing claims,
which are understood as forming an integral part of this
disclosure.
[0016] According to the instant disclosure, the above
object is achieved by a composition comprising chitosan
for use in prevention and/or treatment of incontinence
and/or impotence in a subject undergoing prostatectomy,
preferably radical prostatectomy.
[0017] In one or more embodiments, the composition
comprising chitosan is intended for a surgical application,
specifically for being applied in contact with the prostatic
neurovascular bundle of the subject undergoing prosta-
tectomy.
[0018] Moreover, herein disclosed is a method for pro-
tecting a prostatic neurovascular bundle of a subject,
wherein the composition comprising chitosan, preferably
in a form of a film, is applied in contact with the prostatic
neurovascular bundle of the subject undergoing prosta-
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tectomy.
Brief description of the drawings
[0019] One or more embodiments will now be de-
scribed, purely by way of non-limiting example, with ref-
erence to the annexed drawings, wherein:
- Figure 1: 1H NMR spectrum of native chitosan as
purchased;
- Figure 2: 1H NMR spectrum obtained from chitosan
deacetylated after a hydrolysis step applied to the
commercial product;
- Figure 3: Chitosan composition in form of a solid
film containing holes according to one embodiment
of the instant disclosure;
- Figure 4: Quantitative evaluation of PC3 cancer
cells and RT4-D6P2T glial cells grown in a medium
conditioned with dissolution products of a chitosan
film (CTR = control);
- Figure 5: Regenerative capabilities of dissociated
cultures and ex vivo explants derived from somatic
and autonomic ganglia grown on a chitosan film ac-
cording to one embodiment of the instant disclosure;
- Figure 6: Recovery of potency in patients undergone
radical prostatectomy followed by application of a
composition according to one embodiment of the in-
stant disclosure.
Detailed description
[0020] In the following description, numerous specific
details are given to provide a thorough understanding of
embodiments. The embodiments can be practiced with-
out one or more of the specific details, or with other meth-
ods, components, materials, etc. In other instances, well-
known structures, materials, or operations are not shown
or described in detail to avoid obscuring aspects of the
embodiments.
[0021] Reference throughout this specification to "one
embodiment" or "an embodiment" means that a particular
feature, structure, or characteristic described in connec-
tion with the embodiment is included in at least one em-
bodiment. Thus, the appearances of the phrases "in one
embodiment" or "in an embodiment" in various places
throughout this specification are not necessarily all refer-
ring to the same embodiment. Furthermore, the particular
features, structures, or characteristics may be combined
in any suitable manner in one or more embodiments.
The headings provided herein are for convenience only
and do not interpret the scope or meaning of the embod-
iments.
[0022] In an embodiment, the instant description con-
cerns a chitosan-based composition for use in preventing
and/or treating impotence in a subject undergoing pros-
tatectomy, preferably radical prostatectomy.
[0023] The Inventors of the instant application surpris-
ingly found that a chitosan-based composition as herein
disclosed is able to improve the outcome of the radical
prostatectomy, specifically, achieving a faster recurrence
of potency and a reduced rate of erectile dysfunction in
a subject who underwent radical prostatectomy. In addi-
tion, the composition disclosed herein may allow a faster
recurrence of continence and a reduced rate of inconti-
nence.
[0024] Moreover, thanks to the biocompatibility and to
the antimicrobial and haemostatic properties of chitosan,
inflammation, infection and bleeding time reduction can
also be achieved. The composition herein disclosed has
the further advantage of reducing the risk of infections
thanks to the antibacterial properties of chitosan.
[0025] In one or more embodiments, a high biocom-
patibility and bioactivity of the composition may be ob-
tained by using chitosan in form of native chitosan.
[0026] In the context of the present disclosure, the ex-
pression "native chitosan" refers to the chemical struc-
ture of chitosan, i.e. a poly(N-acetyl-D-glucosamine-co-
D-glucosamine) copolymer or a poly(D-glucosamine)
homopolymer.
[0027] Any cross-linked or otherwise chemically mod-
ified chitosan is considered a chitosan derivative, having
different properties than native chitosan. Crosslinking of
chitosan, either ionically or covalently, may lead to the
blockage of active functionalities of the biomaterial,
namely the amine group.
[0028] In the context of the present disclosure the term
"native chitosan" includes both the chitosan base and
chitosan in form of a chitosan salt.
[0029] In one or more embodiments, the composition
comprises chitosan, preferably chitosan base, in an
amount at least 50%, more preferably at least 90%, more
preferably at least 95% by weight (w/w) of the composi-
tion, based on the non-aqueous components of the com-
position.
[0030] In one or more embodiments, the composition
may comprise chitosan either in form of a base and in
form of a chitosan salt. Preferably, the composition com-
prises at least one chitosan salt in an amount of 50% or
less, more preferably 10% or less, more preferably 5%
or less by weight (w/w) related to the total weight of chi-
tosan.
[0031] The presence of chitosan in form of a salt can
allow a good adhesion of the composition to the neurov-
ascular bundle thus avoiding a premature detachment
from the site of implantation. The chitosan salt is soluble
in an aqueous solvent or physiological medium of neutral
pH. Thus, wet tissue can etch the chitosan film surface,
providing for a durable contact with the prostatic neurov-
ascular bundle.
[0032] In one or more embodiments, chitosan salts
may be derived from the dissolution of chitosan in an
aqueous solution of one or more inorganic acids, such
as hydrochloric acid, and/or organic acids selected from
the group consisting of monobasic or multibasic organic
acids having from 2 to 12 carbon atoms and a first pKa
value between 1 and 5, such as for example acetic acid,
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citric acid, lactic acid, malic acid, succinic acid, mandelic
acid, oxalic acid, tartaric acid, ascorbic acid, etc.
[0033] In one or more embodiments, chitosan may be
present in the composition in form of a chitosan base.
[0034] In one or more embodiments, the composition
consists of chitosan, preferably native chitosan.
[0035] In one or more embodiments, the composition
comprises chitosan with a degree of acetylation of 40%
or less, preferably 20% or less, more preferably 10% or
less.
[0036] In one ore more embodiments, the composition
comprising chitosan herein disclosed is essentially free
of toxic compounds.
[0037] In one or more embodiments, the composition
comprises glycerol in addition to chitosan, preferably in
an amount between 1 and 10 % by weight, based on the
non-aqueous components of the composition.
[0038] The composition herein disclosed is intended
for a surgical application, specifically for application on
the prostatic neurovascular bundle of a subject undergo-
ing prostatectomy.
[0039] The composition according to the present dis-
closure may be in any convenient form for application at
the surgical site, such as solution, powder, microspheres,
flakes, tube, fibres, mesh, coating, or film.
[0040] In one or more embodiments, the composition
herein disclosed is in form of a film, preferably a solid film
or a gel-like film.
[0041] In one or more embodiments, the composition
may be in form of a freeze-dried or solvent-dried bioab-
sorbable film.
[0042] In one or more embodiments, the composition
may be present in form of a flexible film, which may be
continuous or interrupted (e.g. perforated).
[0043] The time of biodegradability of the composition,
for example in form of film, can be tuned by selecting the
degree of acetylation (DA) of chitosan contained therein.
The possibility of tuning the biodegradation time allows
to avoid premature disintegration of the chitosan compo-
sition at the implantation site.
[0044] In one or more embodiments, the composition
comprising chitosan herein disclosed may further com-
prise other components, such as for example at least one
pharmaceutically active and/or bioactive constituent.
[0045] In one or more embodiments, bioactive constit-
uents may be selected from the group consisting of pro-
teins, peptides, nucleic acids, low molecular weight
drugs, such as antibiotics or anti-inflammatory drugs, ag-
onists or antagonists of the innate immune system, stim-
ulating or differentiating growth factors for stimulating or
differentiating growth of at least one cell sub-type, and
mixtures thereof.
[0046] In one or more embodiments, the composition
may further comprise biological cells, such as for exam-
ple adipose-derived stem cells.
[0047] In one ore more embodiments, the composition
may be applied on the prostatic neurovascular bundle of
a subject by spraying or injecting a chitosan solution
which may be derived from the dissolution of chitosan in
an aqueous solution of one or more inorganic acids
and/or organic acids.
[0048] In one or more embodiments, the composition,
for example in form of a film, may be applied on the pro-
static neurovascular bundle of a subject.
[0049] In one or more embodiments, the composition
in form of a solid composition, preferably in form of a film
can have a smooth surface, preferably with an average
roughness Ra of 1 mm (micrometer) or less, preferably
0.5 mm or less, more preferably 0.1 mm or less, as de-
termined by atomic force microscopy.
[0050] Advantageously, a smooth surface can reduce
the mechanical irritation at the implantation site, thereby
reducing the risk of damaging the neurovascular bundle.
[0051] In one or more embodiments, the chitosan com-
position in form of film may present a thickness comprised
between 1 and 1000 mm, preferably between 10 and 100
mm, more preferably between 20 and 50 mm.
[0052] In one or more embodiments, the surface area
of the composition in form of a film may be comprised in
the range between 1 and 50 cm2, preferable between 5
and 25 cm2, more preferably between 10 and 15 cm2.
[0053] Such a surface area allows covering the pros-
tatic neurovascular bundle completely or partially and,
preferably some of the surrounding tissue.
[0054] In one or more embodiments, the composition
herein disclosed, preferably in form of a film, may have
a water uptake capacity of less than 100%, preferably
comprised between 25% and 80% by weight, more pref-
erably between 50% and 75%.
[0055] In one or more embodiments, the chitosan com-
position in form of a film may contain at least one hole
(opening), which allows absorption and diffusion of phys-
iological liquids and fast fluid exchange through the film
bulk structure.
[0056] The at least one hole may have a diameter size
of 1000 mm or less, more preferably 500 mm or less, more
preferably 250 mm or less. In a preferred embodiment,
the at least one hole may have a diameter size of 1 mm
or more, preferably 10 mm or more, more preferably 100
mm or more. In one or more embodiments, the diameter
size of the holes of the film is between 100 mm and 250
mm.
[0057] In one or more embodiments, the holes may
cover an area of 50% or less of the film surface, more
preferably 10% or less, more preferably 1% or less.
[0058] In one or more embodiments, a preferred flow
rate of physiological fluids through the chitosan compo-
sition in form of a film containing holes is 0.001
ml/min/cm2 or more, preferably 0.01 ml/min/cm2 or more,
more preferably 0.1 ml/min/cm2 or more.
[0059] Thanks to this property, the accumulation of flu-
id underneath the composition during implantation can
be reduced or prevented thus favouring its adherence to
the neurovascular bundle.
[0060] In one or more embodiments, the composition
is transparent. Advantageously, this can make it easier
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for a physician to inspect the application to the neurov-
ascular bundle.
[0061] In one or more embodiments, the composition,
once applied at the surgical site, may be sutured.
[0062] Advantageously, this property allows the fixa-
tion of the chitosan-based composition to the surgical
site and prevents dislodgement from the neurovascular
bundle.
[0063] In one or more embodiments, the suture reten-
tion strength based on a Prolene USP 6/0 suture and
evaluated by a mechanical tester is 0.05 N or more, pref-
erably 0.5 N or more when measured in the dry state,
and 0.01 N or more, preferably 0.1 N or more when meas-
ured in the wet state.
Materials and Methods
1H NMR spectroscopy
[0064] Chitosan used as a starting material in the ex-
amples below was obtained in form of fine flakes from
Chitinor (Norway).
[0065] The degree of acetylation (DA) was determined
by 1H NMR spectroscopy, as disclosed in Lavertu et al.,
"A validated 1H NMR method for the determination of the
degree of deacetylation of chitosan", J Pharm Biomed
Anal 2003, 32, 1149.
[0066] Chitosan was analyzed in a mixture of 0.25%
DCl in D2O at a chitosan concentration of approximately
0.5% (w/v).
[0067] The spectra were recorded using a Bruker
Avance III HD 300 spectrometer. The DA, calculated by
comparing the integrated area under the peaks associ-
ated with H2-H6 of the D-glucosamine subunit with that
of the methyl group, was determined as 15.9% for chi-
tosan as purchased, and 5.5% for deacetylated chitosan
obtained as disclosed in the following.
Figure 1 shows a 1H NMR spectrum obtained from
this commercially available chitosan.
Figure 2 shows a corresponding 1H NMR spectrum
obtained from chitosan deacetylated after a further
hydrolysis step applied to the commercial product
as described further below.
Deacetylation of chitosan
[0068] 50 g (grams) of chitosan flakes as obtained from
the supplier Chitinor were placed in a glass container and
500 g of a 45% (w/v) aqueous sodium hydroxide solution
were added.
[0069] The glass container was well shaken to mix the
components, and placed in an oven for 2 hours at 80°C.
It was then removed from the oven and 500 ml (milliliters)
of distilled water were added.
[0070] The mixture was filtered through a 250 mm
sieve. Then, chitosan was washed with distilled water
until the pH of the filtrate reached approx. 6.5, and dried,
resulting in chitosan having a DA of 5.5% as determined
by 1H NMR spectroscopy (Figure 2).
Preparation of a chitosan composition in form of a solid 
film
[0071] 7.5 g of chitosan having a degree of acetylation
of 5% were dissolved in 500 ml of a 0.5% (w/v) aqueous
acetic acid by gently shaking for 24 h.
[0072] 144 ml of the chitosan solution was poured into
a square-shaped mold, 24 x 24 cm2 (square centimetres)
in size, and left in a dust-free environment for drying at
room temperature.
[0073] The dried film was placed for 2 hours in a bath
containing a solution of 1.5% (w/v) ammonia in metha-
nol/water 90/10 (v/v). The film was then removed from
the bath and dried at room temperature. The resulting
film has a content of approx. 100% (w/w) of chitosan,
based on the non-aqueous components of the film. The
remaining water content of the film is less than 10% (w/w).
[0074] A defined pattern of holes of approx. 160 mm
diameter was made by gently rolling a perforator over
the film. Such pattern of holes covers an area of approx.
1% of the film surface.
[0075] Figure 3 shows the resulting perforated film.
The film was then cut into 3 x 4 cm samples, placed in
sterilization bags and sterilized using ethylene oxide.
Water uptake of the composition comprising chitosan in 
form of a solid film
[0076] The composition comprising chitosan in form of
film, produced as described above, was weighted, and
then placed in distilled water for 15 min.
[0077] The weight of the obtained wet film was com-
pared to the weight of the dry film, and the water uptake
was determined to be 55% by weight.
Flow rate through the composition comprising chitosan 
in form of a solid film
[0078] The composition comprising chitosan in form of
a film, produced as described above, was fixed to the
bottom opening of a tube having a diameter of 14 mm
and filled with 5 ml of phosphate buffered solution of pH
7. The flow rate for complete emptying of the tube was
determined as between approx. 0.6 and 1.6 ml/min/cm2.
Suture retention strength of the composition in form of a 
solid film
[0079] The composition comprising chitosan in form of
a solid film, produced as described above, was fixed at
the lower clamp of a mechanical tester (Thümler Z3). A
Prolene USP 6/0 suture was passed through the film and
attached to the upper clamp of the mechanical tester. A
constant speed of 200 mm/min was applied, and the re-
sistance to rupture of the film was determined as 1.06 N
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for dry and 0.17 N for wet (phosphate-buffered solution
at pH 7) film samples.
Cancer cell proliferation evaluation
[0080] The proliferation rate of a PC3 cell line (derived
from a human adenocarcinoma) and of a glial cell line
RT4-D6P2T used as control, was carried out with media
collected after 15 days of chitosan film dissolution.
[0081] The PC3 cell line was purchased from ATCC
(American Type Culture Collection; Manassas, VA, USA
20110-2209), and the RT4-D6P2T cell line was pur-
chased from ATCC (American Type Culture Collection;
Manassas, VA, USA 20110-2209). RT4-D6P2T are rat
peripheral glial cells, derived from a schwannoma.
[0082] Conditioned medium formulations were ob-
tained by incubating the prepared medium (Dulbecco’s
Modified Eagle’s Medium, DMEM, for RT4-D6P2T cell
line and DMEM-F12 medium for PC3 cell line) for 2 weeks
at 37°C and 5% CO2 in the presence of chitosan films (4
chitosan films for 40 ml of culture medium). Afterwards
this medium was used for proliferation experiments.
[0083] As control media, samples of DMEM and
DMEM-F12, without chitosan films, were maintained in
the same conditions (2 weeks at 37°C and 5% CO2), and
then used for proliferation experiments.
Culture Medium Formulations:
[0084] DMEM (SIGMA ALDRICH) supplemented with
100 units·mL-1 penicillin, 0.1 mg·ml-1 streptomycin, 1 mM
sodium pyruvate, 2 mM L-glutamine, 2% heat-inactivated
fetal bovine serum (FBS, Invitrogen).
[0085] DMEM-F12 (SIGMA ALDRICH) supplemented
with 100 units·mL-1 penicillin, 0.1 mg·ml-1 streptomycin,
1 mM sodium pyruvate, 2 mM L-glutamine, 2% heat-in-
activated fetal bovine serum (FBS, Invitrogen).
[0086] 50000 cells (25000 cells/ml) were plated and
cultured in presence of conditioned media and their pro-
liferation was evaluated after 1, 3 and 6 days.
[0087] The number of cells was assessed using a he-
mocytometer chamber. Each experiment was repeated
in triplicate (technical triplicate), to minimize the technical
error, and this was repeated in three independent exper-
iments (biological triplicate), to give the statistical validity.
Data are shown as mean 6 SD.
Regeneration assay
[0088] Harvested dorsal root ganglion (DRGs) and
ganglia of vagus nerve from female adult rats were main-
tained in Leibovitz’s medium (Invitrogen, Monza, Italy)
for 1 hr under sterile conditions. The connective-tissue
capsules were then mechanically reduced and the ex-
plants were half-cut.
[0089] Afterwards the dissociated sensory neurons
from DRG explants (Fig. 5 A-B), and total explants from
the vagus nerve ganglia (Fig. 5 C-D) were adhered onto
matrigel-coated (BD Biosciences, Bedford, MA, USA)
glass coverslips and onto chitosan films, and incubated
at 37 °C for 1 hr before serum-free medium (SFM) was
added.
[0090] Brielfly, SFM medium is composed of 50% (v/v)
F12 nutrient mixture, 50% (v/v) basal medium Eagle
(BME), 2310-3 M glutamine, 0.5% (v/v) 1003 PSN an-
tibiotic mixture (all Invitrogen, Monza, Italy), 10 mg/ml
bovine albumin serum, 1310-4M putrescine, 0.1 mg/ml
transferrin, 3310-8 mg/ml selenium, 0.005 mg/ml insulin,
3.8310-5M vitamin C, 7.5 mg/ml glucose (all Sigma, Mi-
lan, Italy) in culture-grade water. To evaluate the bioac-
tivity (neurite outgrowth inductive potential) of the CS-
substrates the explants were then maintained for three
days in SFM at 37°C with 5% CO2 and and supplied with
150 ng/ml of nerve growth factor (NGF).
[0091] Explants and dissociated cultures were fixed for
15 min in 4% paraformaldehyde (PFA, Sigma-Aldrich,
Seelze, Germany).
[0092] To analyze neurite outgrowth, samples were in-
cubated overnight at 4°C with anti-βIII tubulin (mono-
clonal mouse 1:1000; n. of catalogue: T8660, Sigma
Aldrich) and Schwann cell specific α-S100 antibody
(1:1000; n. of catalogue: HPA015768, Sigma) primary
antibodies followed by 1 hr incubation at room tempera-
ture with secondary antibodies: anti-mouse IgG Alexa-
Fluor-488 conjugated (n. of catalogue: A11029, Life
Technologies) and goat α-rabbit Cy3 (n. of catalogue:
111-165-003, Li Starfish) respectively.
Surgical procedures, application of the composition in 
form of a solid film and clinical evaluation
[0093] A primary outcome of the study was to evaluate
the feasibility of intraoperative application of a chitosan
film produced as disclosed above on neurovascular bun-
dles at the end of a nerve-sparing robot-assisted radical
prostatectomy (RARP).
[0094] Secondary outcomes were the following:
• to assess the early recovery of sexual potency (at 1,
3 and 6 months) and the long term recovery (12
months) after nerve-sparing RARP with chitosan film
(sexual potency recovery was defined as recovery
of spontaneous erections or intercourses);
• to perform a match-paired analysis with patients un-
dergoing nerve sparing RARP without using of pro-
tective chitosan film applied on neurovascular bun-
dles.
Study population
[0095] Patients with an indication for nerve sparing
RARP for prostate cancer were enrolled for the study at
the Urology Department of San Luigi Gonzaga Hospital
(Turin, Italy).
9 10 
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Inclusion criteria
[0096] The inclusion criteria for patient admission to
the study were the following:
• age > 18 years
• informed consent for the study participation
• histological diagnosis of prostate cancer
• indication to nerve sparing RARP
• preoperative IIEF5 Questionnaire > 17
Exclusion criteria
[0097] The exclusion criteria were the following:
• contraindications to RARP
• significant comorbidities (ie. smoking, diabetes mel-
litus, arterial hypertension)
• age > 72 years
Study Design
[0098] Eligible patients in accordance with previous in-
clusion criteria have been submitted to the following proc-
ess:
• Evaluation of inclusion and exclusion criteria;
• Nerve-sparing RARP and intraoperative application
of chitosan film produced as disclosed above on the
neurovascular bundles;
• Uro-oncologic follow-up according to pathological
results (visits at 1, 3, 6, 12 months after surgery);
• Andrologic follow-up (visits at 1, 3, 6, 12 months after
surgery).
Patient sample size (for the match-paired analysis only)
[0099] At least 83 patients (72 + 10-15% to compen-
sate for the drop-out) were admitted to the study.
Statistics
[0100] The sample size, as previously reported, is
based on the match-paired analysis of patients undergo-
ing nerve sparing RARP followed by the application of
the chitosan composition on the neurovascular bundle
vs. patients undergoing nerve sparing RARP without ap-
plication of the chitosan composition on the neurovascu-
lar bundle.
[0101] The sample size was calculated on the basis of
the differences between the two groups obtained from
the analysis of the literature (Rabbani et al., Factors pre-
dicting recovery of erections after radical prostatectomy,
J Urol 2000, 164, 1929; Ficarra et al., Systematic review
and meta-analysis of studies reporting potency rates af-
ter robot-assisted radical prostatectomy, Eur Urol. 2012,
62, 418) which shows that the rate of sexual potency
maintenance after nerve-sparing RARP amount to 50%
while the expected rate after use of chitosan films is more
than 70%.
[0102] To reject the null hypothesis of an equal sexual
potency maintenance rate for both groups 83 patients
have been enrolled in the group of patients undergone
nerve-sparing RARP followed by the application of the
chitosan composition in order to obtain a statistical power
higher than 70% with an accepted error of 0.05.
[0103] Patients in the control group who underwent
nerve sparing RARP without application of the chitosan
composition has been retrospectively selected from the
institutional database of the Urology Department.
[0104] All patients were continent and potent before
RARP, as assessed by validated questionnaires:
• IIEF-5, SEAR and EPIC questionnaires for potency
as disclosed for example in Rosen et al., The inter-
national index of erectile function (IIEF): a multidi-
mensional scale for assessment of erectile dysfunc-
tion, Urology 1997, 49, 822; Zymanski et al., Devel-
opment and validation of an abbreviated version of
the Expanded Prostate Cancer Index Composite In-
strument for measuring health-related quality of life
among prostate cancer survivors, Urology 2010, 76,
1245.
• IPSS and IPSS-QoL for continence as disclosed in
Sarasin et al., Can a urinary tract symptom score
predict the development of postoperative urinary re-
tention in patients undergoing lower limb arthro-
plasty under spinal anaesthesia? A prospective
study. Ann R Coll Surg Engl 2007, 89, 192.
[0105] Nerve bundle preservation during RARP is vital
for improved postoperative potency and continence.
[0106] Radical prostatectomy was performed by using
the intrafascial dissection technique (nerve-sparing) uni-
or bi-lateral.
[0107] Full nerve sparing dissection consists in a dis-
section following a plan on the prostate capsule that is
medial or inner to the prostatic fascia on the anterolateral
and posterolateral face of the prostate and anterior to the
posterior prostatic fascia. The full nerve sparing dissec-
tion allows a complete conservation of the lateral pros-
tatic fascia and then a maintenance of the neurovascular
bundles.
[0108] Partial nerve sparing dissection (50% NS) con-
sists in a dissection which preserves almost half of the
lateral prostatic fascia. Intraoperatively, the right plane
of dissection is identified by the presence of a fat strip
over the prostate.
[0109] A chitosan film produced as disclosed above
having a thickness of 30 mm, holes with a size of 160
mm, and a size of 3 x 4 cm was applied at the end of the
reconstruction phase of the radical prostatectomy.
[0110] The film was immersed in a physiological solu-
tion to allow its insertion through a laparoscopic port and
juxtaposed to the muscular wall where the neurovascular
bundles are located.
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Results
Proliferation rate of cancer cells
[0111] Figure 4 shows PC3 cancer cells grown in a
medium conditioned with the dissolution products of chi-
tosan films; the proliferation rate is lower, starting from
the third day of culture, compared to the proliferation rate
of the same cells cultured in a control medium. The dif-
ference is statistically significant (p<0.05).
[0112] These results thus demonstrate an antiprolifer-
ative activity of the dissolution products of chitosan films
on the tumor cell line PC3.
[0113] The dissolution products of chitosan film do not
cause the same effects on the population of glial cells,
RT4-D6P2T; after six days culture it is possible to ob-
serve a significant increase in their proliferation rate, in-
duced by the conditioned medium.
[0114] The absolutely innovative aspect of chitosan is
represented by the two-fold effect on the tested cell pop-
ulations, in which, on the one hand inhibits the prolifera-
tion of tumor cells and, on the other, promotes the growth
of peripheral nervous glial cells, with a strong regenera-
tive potential.
Nerve regeneration
[0115] The evaluation of the neurons interaction with
the chitosan composition herein disclosed represents a
key preliminary step to establish, in vitro, the potential
for neural regeneration.
[0116] Dissociated neuronal cultures of rat dorsal root
ganglia (DRGs) (Fig. 5 panels A, B) and explants of vagus
nerve ganglia (Fig. 5 panels C, D) are valuable models
to evaluate the neuritic adaptation to different substrates.
[0117] Adults DRGs dissociated neurons and auto-
nomic explants were cultured on chitosan films (Fig. 5,
panels B, C, D) and on glass (Fig. 5, panel A), as positive
control. After three days, a high neurite outgrowth was
appreciated on both substrates. Careful observation led
to detect a great sprouting and neurite extension on the
chitosan films, which represents a permissive substrate
for neurite regeneration, as demonstrated by the β-tubu-
lin positive staining (white) and glial survival, S100 pos-
itive staining (gray).
Clinical evaluation
[0118] The application of the composition comprising
chitosan in form of a film on the neurovascular bundle of
patients undergone RARP resulted in an increase of the
potency recovery. At one month follow-up, potency was
restored in 28.6% of patients with the bilateral full nerve
sparing technique in the control group and in 41% of pa-
tients who underwent the bilateral full nerve sparing tech-
nique followed by the application of the chitosan compo-
sition in form of film (Figure 6).
[0119] The difference in terms of recovery is retained
even three months after surgery; 76.9% of patients who
underwent RARP and the application of the chitosan film
recovered sexual potency vs. the 50% of patients of the
control group (Figure 6).
[0120] Similar results were obtained when comparing
the two groups who underwent bilateral partial nerve
sparing prostatectomy, with and without chitosan film ap-
plication.
[0121] Moreover, it was possible to observe a reduced
inflammation, infection and bleeding time, in the region
of application, due to the biocompatibility, antimicrobial
and haemostatic properties of chitosan films.
[0122] Therefore, the chitosan composition herein dis-
closed is able enhance the recovery of sexual potency
without any adverse effects and without prolonging the
operative time.
[0123] Of course, without prejudice to the underlying
principle, the embodiments and the details of construc-
tion may vary, even significantly, with respect to what
has been illustrated herein purely by way of non-limiting
example, without thereby departing from the extent of
protection. The above extent of protection is defined by
the annexed claims.
Claims
1. Composition comprising chitosan for use in preven-
tion and/or treatment of incontinence and/or impo-
tence in a subject undergoing prostatectomy.
2. Composition for use according to claim 1, wherein
the composition comprises chitosan is an amount of
at least 50% by weight based on the non-aqueous
components of the composition.
3. Composition for use according to any preceding
claims, wherein chitosan has a degree of acetylation
of 40% or less.
4. Composition for use according to any one of the pre-
vious claims, wherein the composition comprises at
least one bioactive constituent, preferably selected
in the group consisting of proteins, peptides, nucleic
acids, drugs and mixture thereof.
5. Composition for use according to any one of the pre-
vious claims, wherein the composition is in form of
of a film, preferably a solid film or a gel-like film.
6. Composition for use according to claim 5, wherein
the film has a thickness of 1000 mm or less, prefer-
ably between 10 and 100 mm, more preferably be-
tween 20 and 50 mm.
7. Composition for use according to claim 5 or 6, where-
in the film contains at least one hole.
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8. Composition for use according to claim 7, wherein
the at least one hole has a mean diameter size of
1000 mm or less, preferably between 10 mm and 500
mm, more preferably between 100 mm and 250 mm.
9. Composition for use according to any one of the pre-
vious claims, wherein the composition has a water
uptake capacity of less than 100% by weight.
10. Composition for use according to any one of the pre-
vious claims, wherein the composition is transpar-
ent.
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